RESEARCHER PROFILE
Patrícia Ashton‐Prolla
← Back to Universidade Federal do Rio Grande do Sul
P
Universidade Federal do Rio Grande do Sul
Patrícia Ashton‐Prolla works in BRCA gene mutations in cancer, Genetic factors in colorectal cancer, Cancer-related Molecular Pathways, Genomics and Rare Diseases, Breast Lesions and Carcinomas. Recorded institutional associations include Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre.
447Publications
5,283Citations
41H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families
2006 · 217 citationsGeographic and age variations in mutational processes in colorectal cancer
2025 · 170 citationsDetailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect
2009 · 153 citationsTSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review
2017 · 153 citationsDetection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil
2008 · 132 citationsFabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes.
2000 · 115 citationsTumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome
2009 · 106 citationsThalidomide, a current teratogen in South America
1996 · 105 citationsGenomic rearrangements in BRCA1 and BRCA2: a literature review
2009 · 102 citationsRecommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
2017 · 91 citationsThe germline mutational landscape of BRCA1 and BRCA2 in Brazil
2018 · 90 citationsAn alternative protocol for DNA extraction from formalin fixed and paraffin wax embedded tissue
2005 · 85 citationsGeographic variation of mutagenic exposures in kidney cancer genomes
2024 · 84 citationsDevelopment and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care
2009 · 80 citationsTP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li–Fraumeni syndrome: impact on age at first diagnosis
2009 · 78 citationsHighly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening?
2009 · 77 citationsPrevalence of the TP53 p.R337H Mutation in Breast Cancer Patients in Brazil
2014 · 75 citationsPregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study
1999 · 74 citationsmiRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma
2015 · 71 citationsPRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines
2014 · 69 citationsImpact of β1-Adrenergic Receptor Polymorphisms on Susceptibility to Heart Failure, Arrhythmogenesis, Prognosis, and Response to Beta-Blocker Therapy
2008 · 67 citationsTP53 mutation p.R337H in gastric cancer tissues of a 12-year-old male child - evidence for chimerism involving a common mutant founder haplotype: case report
2011 · 65 citationsGermline EGFR Mutations and Familial Lung Cancer
2023 · 60 citationsBDNF/TrkB Content and Interaction with Gastrin-Releasing Peptide Receptor Blockade in Colorectal Cancer
2010 · 58 citationsXAF1 as a modifier of p53 function and cancer susceptibility
2020 · 57 citations
